Jounce Therapeutics Inc (JNCE) Return on Assets ROA from the fourth quarter of 2022 to fourth quarter of 2021 and for the year 2022, Average High and Low, Fundamental Ratios from Dec 31 2022 to Dec 31 2021 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Jounce Therapeutics inc   (NASDAQ: JNCE)


Jounce Therapeutics Inc 's ROA from the fourth quarter of 2022 to the fourth quarter of 2021 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Jounce Therapeutics Inc 's ROA in the fourth quarter of 2022?
Jounce Therapeutics Inc recorded a cumulative net loss of $0 million during 12 months ending in the fourth quarter of 2022, resulting in a negative return on assets (ROA) of -0.07%.

However, within the Healthcare sector 246 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2022 from 3073 to 3384.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter		 (Jun 30 2022)
II. Quarter		 (Mar 31 2022)
I. Quarter		 (Dec 31 2021)
IV. Quarter
Y / Y Total Assets Change -15.78 % -43.68 % -38.79 % -29.83 % 5.15 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 0 0 0 0 0
Return On Assets (TTM) -0.07 % -0.01 % -0.01 % -0.01 % -0.01 %
JNCE's Total Ranking # 3384 # 3073 # 3174 # 3183 # 3381
Total Assets (TTM) in million 205 152 179 205 243
Seq. Total Assets Change 35.21 % -15.53 % -12.58 % -15.66 % -9.58 %
Seq. Net Income Change - - - - -

JNCE's 5 Years Annual ROA >> Back to JNCE Management Effectiveness >> Compare JNCE ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 28
Sector # 247
Overall # 3292

Return On Assets Statistics
High Average Low
111.97 %
10.7 %
-65.54 %
(Sep 30 2019)   (Sep 30 2020)





Financial Statements
Jounce Therapeutics Inc 's Assets $ 205 million JNCE's Balance sheet
Jounce Therapeutics Inc 's Income $ 0 million Quarterly JNCE's Income Statement
JNCE's Income by Division See JNCE's Income by Division



Annual Return On Assets (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021		 (Dec 31 2020)
FY 2020		 (Dec 31 2019)
FY 2019		 (Dec 31 2018)
FY 2018
Y / Y Total Assets Change -15.78 % 5.15 % 21.83 % -11.42 % -27.71 %
Total Assets in million 205 243 231 190 214
Y / Y Net Income Change - - - - -
Net Income in million 0 0 0 114 0
Annual Return On Assets -0.07 % -0.01 % -0.01 % 59.85 % -0.02 %

JNCE's 5 Years Annual ROA >> Back to JNCE Management Effectiveness >> Compare JNCE ROA to its Competitors



More Return On Assets Ratios
JNCE's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
JNCE's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for JNCE's Competitors
Subscribers only: Roa for Jounce Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for JNCE's Customers

You may also want to know
JNCE's Roi JNCE's Inventory Turnover Ratio JNCE's Growth Rates JNCE's Dividend Comparisons
JNCE's Profitability Ratios JNCE's Asset Turnover Ratio JNCE's Dividend Growth
JNCE's Roe JNCE's Valuation Ratios JNCE's Financial Strength Ratios JNCE's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2022, within Healthcare Sector ROA

Date modified: 2026-09-18T13:11:05+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.